MARKET

CUE

CUE

Cue Biopharma Inc
NASDAQ
0.3201
+0.0040
+1.27%
After Hours: 0.3194 -0.0007 -0.22% 18:54 02/06 EST
OPEN
0.3146
PREV CLOSE
0.3161
HIGH
0.3270
LOW
0.3034
VOLUME
379.66K
TURNOVER
--
52 WEEK HIGH
1.540
52 WEEK LOW
0.2302
MARKET CAP
29.21M
P/E (TTM)
-0.7029
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CUE last week (0126-0130)?
Weekly Report · 5d ago
Weekly Report: what happened at CUE last week (0119-0123)?
Weekly Report · 01/26 10:00
Biotech Sector Sees Broad After-Hours Gains Amid Quiet News Flow
NASDAQ · 01/23 04:42
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 01/22 21:05
Cue Biopharma’s CUE-101 Trial Hits Completion: What It Means for Cancer Investors
TipRanks · 01/22 16:30
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 01/22 12:05
Biotech Stocks Surge After Hours: IO Biotech Jumps 19%, Cue Biopharma And Cabaletta Bio Follow
NASDAQ · 01/22 04:12
Weekly Report: what happened at CUE last week (0112-0116)?
Weekly Report · 01/19 10:05
More
About CUE
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.

Webull offers Cue Biopharma Inc stock information, including NASDAQ: CUE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CUE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CUE stock methods without spending real money on the virtual paper trading platform.